A Multicenter Open-label Extension Study to Assess the Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2017
At a glance
- Drugs LYC 30937 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Lycera
- 23 Feb 2017 Time frame of primary endpoint has changed from 6 weeks to 46 weeks.
- 13 Dec 2016 Status changed from not yet recruiting to recruiting.
- 09 May 2016 Status changed from planning to not yet recruiting.